Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy (PhenoRXPrag)

July 23, 2026 updated by: Phenomix Sciences

Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy (PhenoRX Pragmatic Trial)

A pragmatic, randomized, parallel-arm, controlled study of weight loss outcomes using AOMs guided by MyPhenome test.

Study Overview

Status

Not yet recruiting

Study Type

Interventional

Enrollment (Estimated)

424

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults - age 18 or older
  • obesity (BMI ≥ 30 kg/m2) without obesity related diseases (ORDs). Or obesity (BMI ≥ 27 kg/m2) with obesity related diseases (ORDs).
  • Mayo Clinic employee or dependent
  • Referred to Community Internal Medicine Weight Management Program

Exclusion Criteria:

  • Pregnancy or currently breast feeding.
  • No contraindications to the weight loss medications: Phentermine-Topiramate Extended Release (Qsymia®); Oral naltrexone extended-release/bupropion extended-release (NBSR; Contrave®, Mysimba™); Liraglutide (Saxenda®), Semaglutide (Wegovy®), and Tirzepatide (Zepbound®).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard of Care Medication Selection
Patients randomized to this group will be prescribed the medications based on Mayo Clinic Community Internal Medicine Weight Management Program guidelines.
Available AOMs will be: GLP-1 Receptor Agonists (semaglutide or tirzepatide), Phentermine-Topiramate ER, and naltrexone-bupropion SR
Experimental: MyPhenome Test
Patients randomized to this group will take the MyPhenome Test. Results will be returned and the High CTSGRS (Hungry Brain) phenotype will be assigned to Phentermine-topiramate ER, low CTSGRS (Hungry Gut) phenotype will be assigned to GLP-1 receptor agonists (semaglutide or tirzepatide) and the emotional eating phenotype will be assigned to naltrexone-bupropion SR.
Available AOMs will be: GLP-1 Receptor Agonists (semaglutide or tirzepatide), Phentermine-Topiramate ER, and naltrexone-bupropion SR
The MyPhenome test is a genetic and clinical assessment that classifies individuals into biologically defined obesity phenotypes to guide personalized treatment. Using a saliva DNA sample combined with brief clinical inputs, the test predicts whether a patient has abnormalities in high CTSGRS ("Hungry Brain"), low CTSGRS ("Hungry Gut"), or hedonic eating ("Emotional Hunger").
Other Names:
  • MyPhenome Test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Body Weight Loss (TBWL) at 6 Months %
Time Frame: 6-Months
TWBL% at 6 months
6-Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
TBWL% at 3 Months
Time Frame: 3-months
TBWL% at 3 Months
3-months
TBWL% at 9 Months
Time Frame: 9-Months
TBWL% at 9 Months
9-Months
TBWL% at 12 Months
Time Frame: 12-Months
TBWL% at 12 Months
12-Months
TBWL% at 18 Months
Time Frame: 18-Months
TBWL% at 18 Months
18-Months
TBWL% at 24 Months
Time Frame: 24-Months
TBWL% at 24 Months
24-Months
Degree of Treatment Response
Time Frame: 6-Months
6-Months: non-responsive (<3% TBWL), partial responsive (3%-15% TBWL), successful (>15%-20% TBWL) and highly successful (>20% TBWL)
6-Months
Cost of Treatment
Time Frame: 3, 6, 9, 12, 18, 24 Months
Cost of Treatment
3, 6, 9, 12, 18, 24 Months
Cost-Effectiveness
Time Frame: 3, 6, 9, 12, 18, 24 Months

Cost-Effectiveness

Pharmacy resource utilization data will be collected during the study. Pharmacotherapy costs will be directly compared between control and intervention groups and compared to weight loss outcomes.

3, 6, 9, 12, 18, 24 Months
Patient Satisfaction
Time Frame: 3, 6, 9, 12, 18, 24 Months
Client Satisfaction Questionnaire (CSQ-8): Given the design of the study, we will measure and evaluate patient satisfaction with a program of care rather than satisfaction with a specific medication. The satisfaction with the program will be evaluated with the adapted Client Satisfaction Questionnaire (CSQ-8). This is an 8-item measure that captures overall satisfaction with the care received, including perceived quality, whether care met patient needs, and willingness to recommend the program (each item score 1-4). The items will be lightly adapted to refer to weight management care with a total score ranging from 8 to 32 .
3, 6, 9, 12, 18, 24 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

January 1, 2029

Study Registration Dates

First Submitted

July 10, 2026

First Submitted That Met QC Criteria

July 23, 2026

First Posted (Actual)

July 27, 2026

Study Record Updates

Last Update Posted (Actual)

July 27, 2026

Last Update Submitted That Met QC Criteria

July 23, 2026

Last Verified

July 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe